CN110785176A - 病毒样颗粒 - Google Patents

病毒样颗粒 Download PDF

Info

Publication number
CN110785176A
CN110785176A CN201880042333.7A CN201880042333A CN110785176A CN 110785176 A CN110785176 A CN 110785176A CN 201880042333 A CN201880042333 A CN 201880042333A CN 110785176 A CN110785176 A CN 110785176A
Authority
CN
China
Prior art keywords
nucleic acid
artificial nucleic
acid cassette
artificial
cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880042333.7A
Other languages
English (en)
Chinese (zh)
Inventor
日尔曼·列昂诺夫
西蒙·怀特
彼得·斯托克利
尼克什·帕特尔
埃玛·弗罗布莱斯基
丹·马斯克尔
雷顿·特瓦洛克
理查德·宾厄姆
伊娃·韦斯
埃里克·戴克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leeds
University of York
Original Assignee
University of Leeds
University of York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leeds, University of York filed Critical University of Leeds
Publication of CN110785176A publication Critical patent/CN110785176A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8283—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for virus resistance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201880042333.7A 2017-06-01 2018-05-31 病毒样颗粒 Pending CN110785176A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1708709.9A GB201708709D0 (en) 2017-06-01 2017-06-01 Virus like particle
GB1708709.9 2017-06-01
PCT/GB2018/051475 WO2018220371A1 (en) 2017-06-01 2018-05-31 Virus like particle

Publications (1)

Publication Number Publication Date
CN110785176A true CN110785176A (zh) 2020-02-11

Family

ID=59349926

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880042333.7A Pending CN110785176A (zh) 2017-06-01 2018-05-31 病毒样颗粒

Country Status (9)

Country Link
US (1) US12209241B2 (https=)
EP (1) EP3612189B1 (https=)
JP (1) JP7242561B2 (https=)
KR (1) KR102659943B1 (https=)
CN (1) CN110785176A (https=)
AU (1) AU2018277132A1 (https=)
CA (1) CA3064354A1 (https=)
GB (1) GB201708709D0 (https=)
WO (1) WO2018220371A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687942A (zh) * 2011-05-13 2014-03-26 弗利亚生物技术公司 病毒样颗粒及其制备方法
WO2015033155A1 (en) * 2013-09-05 2015-03-12 The University Of York Anti-viral therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1015561B1 (en) 1997-09-05 2006-07-19 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
AUPQ912000A0 (en) * 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
WO2005012535A2 (en) * 2003-08-01 2005-02-10 Phytovation B.V. Method for producing life attenuated viruses and use of viral particles thus produced.
GB0318704D0 (en) 2003-08-08 2003-09-10 Sirus Pharmaceuticals Ltd Chimaeric vector system
DE10345798A1 (de) 2003-09-30 2005-04-14 Basf Ag Aminogruppenhaltige Ethylencopolymerwachse und ihre Verwendung
US20080044437A1 (en) 2004-09-02 2008-02-21 Qun Chen Encapsidation System for Production of Recombinant Virus-Like Particles
WO2014093965A1 (en) * 2012-12-14 2014-06-19 Case Western Reserve University Genomic rna packaging enhancer element

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687942A (zh) * 2011-05-13 2014-03-26 弗利亚生物技术公司 病毒样颗粒及其制备方法
WO2015033155A1 (en) * 2013-09-05 2015-03-12 The University Of York Anti-viral therapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ERIC C. DYKEMAN等: "Solving a Levinthal’s paradox for virus assembly identifies a unique antiviral strategy", 《PNAS》, vol. 111, no. 14, pages 5361 - 5366, XP055444531, DOI: 10.1073/pnas.1319479111 *
H. STEWART等: "Identification of novel RNA secondary structures within the hepatitis C virus genome reveals a cooperative involvement in genome packaging", 《SCIENTIFIC REPORTS》, vol. 6, pages 1 - 12 *
NIKESH PATEL等: "The HBV RNA pre-genome encodes specific motifs that mediate interactions with the viral core protein that promote nucleocapsid assembly", 《NAT. MICROBIOL.》, vol. 2, pages 1 - 26 *
ÓTTAR ROLFSSON等: "Direct Evidence for Packaging Signal-Mediated Assembly of Bacteriophage MS2", 《J.MOL.BIOL》, vol. 428, pages 431 - 448, XP029407036, DOI: 10.1016/j.jmb.2015.11.014 *
PETER E. PREVELIGE JR.: "Follow the Yellow Brick Road: A Paradigm Shift in Virus Assembly", 《J.MOL.BIOL》, vol. 428, pages 416 - 418, XP029407038, DOI: 10.1016/j.jmb.2015.12.009 *
ROBERT J. FORD等: "Sequence-Specific, RNA-Protein Interactions Overcome Electrostatic Barriers Preventing Assembly of Satellite Tobacco Necrosis Virus Coat Protein", 《J.MOL.BIOL.》, vol. 425, 11 January 2013 (2013-01-11), pages 1050 - 1064, XP028989269, DOI: 10.1016/j.jmb.2013.01.004 *

Also Published As

Publication number Publication date
EP3612189B1 (en) 2023-09-27
US20200165613A1 (en) 2020-05-28
KR102659943B1 (ko) 2024-04-24
JP7242561B2 (ja) 2023-03-20
US12209241B2 (en) 2025-01-28
EP3612189A1 (en) 2020-02-26
GB201708709D0 (en) 2017-07-19
AU2018277132A1 (en) 2020-01-02
JP2020529391A (ja) 2020-10-08
KR20200015570A (ko) 2020-02-12
WO2018220371A1 (en) 2018-12-06
CA3064354A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
US20220362315A1 (en) Anellovirus compositions and methods of use
Chavda et al. Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world
Ye et al. The mRNA vaccine revolution: COVID-19 has launched the future of vaccinology
BE1024796B9 (fr) Constructions antigeniques du virus zika
BE1025121B1 (fr) Constructions antigeniques du virus zika
JP7776176B2 (ja) 環状ｒｎａを調製するための構築物及び方法
JP2024520534A (ja) 環状ｒｎａを調製するための構築物及び方法並びにその使用
CN119193702A (zh) 经由改造的adar募集的rna和dna碱基编辑
CN102858960B (zh) 用于在rna噬菌体的病毒样颗粒上进行肽展示和亲和选择的质粒和方法
EP3847650A1 (en) Nucleic acid assemblies for use in targeted delivery
WO2023064907A1 (en) Compositions and methods for vaccination against pathogenic coronavirus species and variants
US20250339508A1 (en) Therapeutic interfering particles for corona virus
US20220042042A1 (en) Anellosomes and methods of use
JP2022512395A (ja) 分泌治療モダリティを送達するためのアネロソーム
Fok et al. Genetic‐code‐expansion strategies for vaccine development
US20220040117A1 (en) Anellosomes for delivering intracellular therapeutic modalities
CN119110847A (zh) 针对sars-cov-2变体的环状rna疫苗及其使用方法
JP7242561B2 (ja) ウイルス様粒子
CA3155202A1 (en) Synthetic rig-i-like receptor agonists
WO2022221699A1 (en) Genetic modification of hepatocytes
HK40104540A (zh) 制备环形rna的构建体、方法及其用途
Nease Interaction Between Chikungunya Virus RNA and Capsid Protein Regulated Viral Replication
CN120608081A (zh) 制备环形rna的构建体、方法及其用途
HK40119906A (zh) 针对sars-cov-2变体的环状rna疫苗及其使用方法
CN120608082A (zh) 制备环形rna的构建体、方法及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200211

WD01 Invention patent application deemed withdrawn after publication